News
Lysogene Announces Termination of License Agreement With Sarepta for LYS-SAF302 Program, Regaining Global Commercial Rights
Regulatory News:
Lysogene (FR0013233475 – LYS) (Paris:LYS), a gene therapy platform company targeting central nervous system (CNS) diseases, today announced the termination of its license
Pulse Biosciences Announces Preliminary Fourth Quarter and Full Year 2021 Financial and Operational Results
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced preliminary
CI Financial to Acquire Northwood Family Office, Canada’s Leading Multi-Family Office
CI Financial Corp. (“CI”) (TSX: CIX; NYSE: CIXX) and Northwood Family Office Ltd. (“Northwood”) today announced an agreement under which CI will acquire Northwood, Canada’s leading multi-family
Lucid Diagnostics to Participate in a Fireside Chat at the 24th Annual Needham Virtual Growth Conference
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”)
Granite REIT Notice of Conference Call for Fourth Quarter and Year-End 2021 Results
Granite Real Estate Investment Trust (“Granite”) (TSX: GRT.UN / NYSE: GRP.U) expects to announce its financial results for the fourth quarter and year-ended December 31, 2021 after the close of
CI Financial Completes Six Transactions, Boosting U.S. Assets to US$115 Billion
CI Financial Corp. (“CI”) (TSX: CIX, NYSE: CIXX) today announced it has completed the acquisitions of four registered investment advisor firms, adding approximately US$24 billion in assets to its
ABIONYX Pharma Announces That the French Drug Safety Agency (Agence Nationale de Sécurité du Médicament or ANSM) Has Granted a Compassionate Access Authorization for the bio-HDL (CER-001) in COVID-19 Disease
ABIONYX Pharma (FR0012616852 – ABNX – PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, today announces that the
CI Global Asset Management Announces Confirmed Annual Reinvested Capital Gains Distributions for CI ETFs
CI Global Asset Management (“CI GAM”) announces the confirmed annual reinvested capital gains distributions (the “Reinvested Distributions”) for the 2021 tax year for the CI ETFs listed below.